OR25-07 A Multi-Center, Open-Label, Pivotal Phase 2 Study of Azedra® (HSA I-131-MIBG) in Patients with Unresectable, Locally Advanced or Metastatic Pheochromocytoma or Paraganglioma: Updated Long-Term Survival and Safety

Background: Pheochromocytoma/Paraganglioma (PPGL) are rare neuroendocrine tumors with a 5-yr survival rate as low as 12%. There is a high unmet medical need for effective treatment options for patients with advanced disease. AZEDRA(®), a high-specific-activity iodine-131 meta-iodobenzylguanidine (HS...

Descripción completa

Detalles Bibliográficos
Autores principales: Jimenez, Camilo, Chin, Bennett B, Noto, Richard B, Dillon, Joseph Stephen, Solnes, Lilja B, DiPippo, Vincent A, Stambler, Nancy, Wong, Vivien, Pryma, Daniel A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Adrenal
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7208024/
http://dx.doi.org/10.1210/jendso/bvaa046.1241

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7208024/
http://dx.doi.org/10.1210/jendso/bvaa046.1241

Ejemplares similares